The Therapeutic Goods Administration routinely prepares cost recovery implementation statements (CRIS).
Definition
In essence, a CRIS transparently documents how an agency's fees and charges comply with its cost recovery policy and with the Australian Government Cost Recovery Guidelines.
Background
In December 2002 the Australian Government adopted a formal cost recovery policy to improve the consistency, transparency and accountability of its cost recovery arrangements and to promote the efficient allocation of resources. The underlying principle of the policy is that entities should set charges to recover all the costs of products or services where it is efficient and effective to do so, where the beneficiaries are a narrow and identifiable group and where charging is consistent with Australian Government policy objectives.
Cost recovery policy is administered by the Department of Finance and Deregulation and outlined in the Cost Recovery Guidelines.
When is a CRIS prepared?
According to the Guidelines, a CRIS should be prepared for significant cost recovery arrangements, when:
- reviews consistent with the Australian Government's review schedule for existing cost recovery arrangements are undertaken;
- new cost recovery arrangements are proposed;
- material amendments are made to existing arrangements (a general rule-of-thumb is that price changes greater than the Consumer Price Index would be considered material - however, agencies should also consider the likely impact on stakeholders); and
- periodic reviews of cost recovery arrangements are undertaken.
A CRIS differs from a Regulation Impact Statement (RIS), which is required for proposed regulation (or amendment to regulation) that affects business.
TGA cost recovery implementation statements
- Cost recovery implementation statement
This document provides information on how the Therapeutic Goods Administration (TGA) implements cost recovery of regulatory activities.
Previous cost recovery impact statements are available in TROVE.